Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;9(3):183-94.
doi: 10.1038/nrrheum.2013.5. Epub 2013 Feb 5.

Creative Trial Design in RA: Optimizing Patient Outcomes


Creative Trial Design in RA: Optimizing Patient Outcomes

Maya H Buch et al. Nat Rev Rheumatol. .


The rheumatology community has witnessed remarkable advances in the management of rheumatoid arthritis (RA) made possible by the development of highly effective biologic DMARDs. Robust randomized controlled trials of clinical efficacy, equipped with validated outcome measures, ensured these therapies could enter the clinical arena and thus substantially improve patient outcomes. Current management principles, which follow a 'treat-to-target' paradigm, advocate tight control of disease activity with the aim of achieving clinical remission. However, efficacy trials are not yet aligned with this approach, hampering patient recruitment. This impediment and the usual approach of inclusion of previously failed treatment arms (to protect methodological concerns) is prompting reappraisal of RA trial design and the consideration of more pragmatic studies that reflect real-life practice. In addition, the aspirations of the rheumatology community to strive for personalized medicine means innovative approaches to trial design are needed to complement the efficacy trial. This Review appraises the current trial landscape and provides insights and key concepts from other fields such as oncology as to the potential utility (as well as the limitations) of pragmatic trial designs such as adaptive trials and biomarker-driven trials.

Similar articles

See all similar articles

Cited by 5 articles


    1. J Rheumatol. 2011 Sep;38(9):2063-7 - PubMed
    1. Lancet. 1996 Feb 10;347(8998):347-52 - PubMed
    1. Lancet. 1999 Dec 4;354(9194):1932-9 - PubMed
    1. Clin Pharmacol Ther. 2001 Mar;69(3):89-95 - PubMed
    1. Ann Rheum Dis. 2013 Jan;72 (1):64-71 - PubMed

Publication types

MeSH terms